
Deepak Ben Vangala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4394986/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adenoma and colorectal cancer risks in Lynch syndrome, Lynchâ€like syndrome and familial colorectal cancer type X. International Journal of Cancer, 2022, 150, 56-66.	5.1	2
2	Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in <scp>AML</scp> / <scp>MDS</scp> patients. International Journal of Cancer, 2022, 150, 1998-2011.	5.1	32
3	Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs therapy. Haematologica, 2022, , .	3.5	0
4	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity. Cancers, 2022, 14, 2100.	3.7	7
5	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	5.1	9
6	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
7	Value of upper <scp>gastrointestinal</scp> endoscopy for gastric cancer surveillance in patients with Lynch syndrome. International Journal of Cancer, 2021, 148, 106-114.	5.1	28
8	Case Report: Hemophagocytic Lymphohistiocytosis and Non-Tuberculous Mycobacteriosis Caused by a Novel GATA2 Variant. Frontiers in Immunology, 2021, 12, 682934.	4.8	6
9	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	2.8	11
10	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
11	Early detection of duodenal cancer by upper <scp>gastrointestinal</scp> â€endoscopy in Lynch syndrome. International Journal of Cancer, 2021, 149, 2052-2062.	5.1	4
12	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Medicine, 2021, 13, 116.	8.2	10
13	Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report. Frontiers in Oncology, 2021, 11, 706431.	2.8	1
14	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
15	Quantification of cell-free DNA for the analysis of CD19-CAR-T cells during lymphoma treatment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 539-550.	4.1	6
16	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
17	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290.	2.4	12
18	Ageâ€dependent performance of <scp><i>BRAF</i></scp> mutation testing in Lynch syndrome diagnostics. International Journal of Cancer, 2020, 147, 2801-2810.	5.1	17

DEEPAK BEN VANGALA

#	Article	IF	CITATIONS
19	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	1.3	60
20	Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma. Haematologica, 2020, 105, e160-e163.	3.5	10
21	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. BMC Cancer, 2020, 20, 460.	2.6	32
22	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
23	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO)Âexpert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. European lournal of Cancer. 2018. 104. 91-103.	2.8	60
24	Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. International Journal of Cancer, 2018, 143, 2800-2813.	5.1	11
25	Value of EGD for gastric cancer surveillance in patients with hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome (LS) Journal of Clinical Oncology, 2018, 36, 1522-1522.	1.6	4
26	Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas Journal of Clinical Oncology, 2018, 36, 1555-1555.	1.6	3
27	Bloodâ€based detection of <i><scp>RAS</scp></i> mutations to guide antiâ€< scp>EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissueâ€based <i><scp>RAS</scp></i> testing. Molecular Oncology, 2017, 11, 208-219.	4.6	125
28	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349